Trial Profile
Efficacy of Ibrutinib in Patients with Bing-Neel Syndrome
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jan 2019
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Therapeutic Use
- 04 Dec 2018 Results (n=24) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 26 Jul 2018 New trial record
- 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association